Index RUT
P/E -
EPS (ttm) -0.25
Insider Own 52.98%
Shs Outstand 773.28M
Perf Week 2.44%
Market Cap 878.21M
Forward P/E -
EPS next Y -0.26
Insider Trans 3.16%
Shs Float 327.73M
Perf Month 17.76%
Income -188.89M
PEG -
EPS next Q -0.10
Inst Own 27.41%
Short Float 23.81%
Perf Quarter 27.97%
Sales 863.49M
P/S 1.02
EPS this Y -46.29%
Inst Trans -3.05%
Short Ratio 8.61
Perf Half Y -0.79%
Book/sh 1.80
P/B 0.70
EPS next Y 29.96%
ROA -9.04%
Short Interest 78.03M
Perf Year -9.35%
Cash/sh 0.14
P/C 9.16
EPS next 5Y 12.00%
ROE -12.80%
52W Range 0.85 - 2.24
Perf YTD -16.56%
Dividend Est. -
P/FCF -
EPS past 5Y 1.56%
ROI -11.29%
52W High -43.75%
Beta 1.81
Dividend TTM -
Quick Ratio 1.22
Sales past 5Y 3.29%
Gross Margin 26.88%
52W Low 47.96%
ATR (14) 0.06
Dividend Ex-Date -
Current Ratio 1.55
EPS Y/Y TTM 44.76%
Oper. Margin -18.31%
RSI (14) 58.31
Volatility 3.78% 5.89%
Employees 3930
Debt/Eq 0.24
Sales Y/Y TTM -14.02%
Profit Margin -21.87%
Recom 1.00
Target Price 4.25
Option/Short Yes / Yes
LT Debt/Eq 0.20
EPS Q/Q 22.10%
Payout -
Rel Volume 0.21
Prev Close 1.22
Sales Surprise 2.46%
EPS Surprise 10.00%
Sales Q/Q -1.89%
Earnings Feb 27 AMC
Avg Volume 9.06M
Price 1.26
SMA20 -1.43%
SMA50 15.45%
SMA200 -9.56%
Trades
Volume 1,946,474
Change 3.28%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-29-23 Upgrade
Barrington Research
Mkt Perform → Outperform
$2
Dec-15-22 Initiated
H.C. Wainwright
Buy
$3
Jan-24-22 Downgrade
Barrington Research
Outperform → Mkt Perform
Jun-21-21 Initiated
Ladenburg Thalmann
Buy
$7
Nov-25-19 Initiated
Piper Jaffray
Overweight
$2.50
Mar-02-18 Downgrade
JP Morgan
Neutral → Underweight
Sep-14-17 Downgrade
JP Morgan
Overweight → Neutral
Jun-21-16 Reiterated
Standpoint Research
Buy
$16 → $18
Jun-03-16 Initiated
Standpoint Research
Buy
$16
Mar-31-16 Reiterated
Barrington Research
Outperform
$17 → $16
Oct-16-15 Initiated
JP Morgan
Overweight
$14
Sep-11-15 Downgrade
Jefferies
Buy → Hold
Mar-03-15 Downgrade
Oppenheimer
Outperform → Perform
May-12-14 Reiterated
Oppenheimer
Outperform
$13 → $12
Mar-14-14 Initiated
Oppenheimer
Outperform
$13
Nov-13-13 Reiterated
Ladenburg Thalmann
Buy
$10 → $14.50
May-30-13 Reiterated
Ladenburg Thalmann
Buy
$8.50 → $10
Oct-22-12 Initiated
Barrington Research
Outperform
$6
Dec-01-11 Reiterated
Ladenburg Thalmann
Buy
$6 → $8.50
Jul-14-11 Initiated
Ladenburg Thalmann
Buy
$6
Show Previous Ratings
Apr-01-24 01:01PM
Mar-28-24 11:08PM
08:00AM
Mar-25-24 09:57AM
Mar-20-24 08:00AM
08:52AM
Loading…
Mar-05-24 08:52AM
Feb-29-24 08:31AM
Feb-28-24 09:31AM
09:02AM
06:18AM
(Thomson Reuters StreetEvents)
Feb-27-24 09:00PM
07:30PM
06:10PM
05:08PM
(Associated Press Finance)
04:43PM
04:05PM
Loading…
04:05PM
Feb-26-24 09:16AM
Feb-22-24 04:05PM
Feb-08-24 01:48PM
Feb-05-24 08:09AM
Jan-22-24 11:48AM
Jan-09-24 04:05PM
Jan-08-24 08:00AM
Jan-04-24 11:31PM
Jan-03-24 05:05PM
Dec-07-23 10:20AM
Dec-06-23 11:30AM
Nov-28-23 07:00AM
Nov-07-23 10:36AM
(Thomson Reuters StreetEvents)
10:29AM
09:19AM
Loading…
09:19AM
06:45AM
01:00AM
Nov-06-23 07:30PM
05:30PM
(Associated Press Finance)
05:01PM
04:05PM
Nov-02-23 10:00AM
Oct-31-23 08:00AM
Oct-25-23 04:25PM
Oct-12-23 10:50AM
Oct-06-23 12:03PM
Sep-29-23 01:03PM
Sep-28-23 07:36PM
04:08PM
Sep-13-23 01:18PM
Sep-12-23 08:30AM
Aug-28-23 11:56AM
Aug-07-23 01:21PM
Aug-04-23 01:00AM
Aug-03-23 05:55PM
04:48PM
04:05PM
Jul-25-23 04:05PM
Jul-23-23 08:11AM
Jul-12-23 08:25AM
Jun-29-23 03:51PM
11:23AM
09:53AM
08:10AM
Jun-28-23 07:03AM
06:51AM
06:45AM
Jun-08-23 07:11AM
Jun-02-23 11:31AM
May-10-23 06:13AM
May-04-23 12:23PM
05:48AM
(Thomson Reuters StreetEvents)
May-03-23 10:00PM
06:25PM
05:23PM
04:05PM
Apr-25-23 04:05PM
Apr-13-23 07:46AM
Mar-17-23 06:21AM
Mar-14-23 12:08PM
Mar-09-23 03:42PM
08:00AM
Mar-08-23 04:34PM
12:01PM
08:05AM
08:01AM
08:00AM
Feb-26-23 07:13AM
06:40AM
Feb-24-23 10:43AM
07:11AM
(Thomson Reuters StreetEvents)
01:00AM
Feb-23-23 04:05PM
Feb-16-23 12:17PM
11:41AM
Feb-13-23 06:03AM
Feb-09-23 07:05AM
Jan-14-23 07:26AM
Jan-03-23 08:00AM
Dec-28-22 10:06AM
Nov-29-22 10:47AM
Nov-16-22 05:08AM
Nov-09-22 08:39AM
Nov-08-22 08:30PM
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
FROST PHILLIP MD ET AL CEO & Chairman Mar 18 '24 Buy 0.87 500,000 437,100 210,968,225 Mar 18 04:45 PM FROST PHILLIP MD ET AL CEO & Chairman Mar 14 '24 Buy 0.89 500,000 444,300 210,468,225 Mar 14 05:00 PM FROST PHILLIP MD ET AL CEO & Chairman Mar 13 '24 Buy 0.93 500,000 463,750 209,968,225 Mar 13 04:44 PM FROST PHILLIP MD ET AL CEO & Chairman Mar 12 '24 Buy 0.93 600,000 559,380 209,468,225 Mar 12 05:27 PM FROST PHILLIP MD ET AL CEO & Chairman Feb 28 '24 Buy 0.99 500,000 496,150 208,868,225 Feb 28 05:31 PM FROST PHILLIP MD ET AL CEO & Chairman Feb 21 '24 Buy 0.99 1,000,000 991,700 208,368,225 Feb 21 05:10 PM FROST PHILLIP MD ET AL CEO & Chairman Feb 07 '24 Buy 0.98 1,500,000 1,462,800 207,368,225 Feb 07 05:09 PM KRASNO RICHARD M Director Jan 29 '24 Buy 0.99 30,000 29,838 103,333 Jan 29 03:30 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 19 '24 Buy 0.98 500,000 488,650 205,868,225 Jan 19 04:54 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 18 '24 Buy 0.97 400,000 386,200 205,368,225 Jan 18 05:06 PM HSIAO JANE PH D Vice Chairman & CTO Jan 17 '24 Buy 0.95 150,000 142,500 27,999,880 Jan 17 05:09 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 16 '24 Buy 0.95 1,000,000 954,300 204,968,225 Jan 16 05:03 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 11 '24 Buy 0.94 511,531 480,379 203,968,225 Jan 11 05:15 PM Nabel Gary J. Chief Innovation Officer Jan 08 '24 Buy 0.93 216,184 200,427 351,442 Jan 10 05:56 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 05 '24 Buy 0.90 1,500,000 1,344,600 203,456,694 Jan 08 08:54 AM Zerhouni Elias A. Vice Chairman and President Jan 05 '24 Buy 0.93 550,300 514,093 20,327,814 Jan 05 05:26 PM HSIAO JANE PH D Vice Chairman & CTO Jan 05 '24 Buy 0.87 150,010 130,899 27,849,880 Jan 08 09:10 AM PFENNIGER RICHARD C JR Director Jan 05 '24 Buy 0.94 25,000 23,429 325,000 Jan 05 12:42 PM PAGANELLI JOHN A Director Jan 05 '24 Buy 0.88 25,000 22,080 384,340 Jan 05 04:00 PM Rubin Steven D Executive VP-Administration Jan 05 '24 Buy 0.87 10,000 8,669 6,187,732 Jan 05 01:39 PM PFENNIGER RICHARD C JR Director Nov 13 '23 Buy 1.30 25,000 32,491 300,000 Nov 14 07:10 AM FROST PHILLIP MD ET AL CEO & Chairman Nov 10 '23 Buy 1.25 500,000 625,462 201,956,694 Nov 13 08:23 AM HSIAO JANE PH D Vice Chairman & CTO Nov 10 '23 Buy 1.27 100,000 126,659 27,699,870 Nov 13 08:21 AM Rubin Steven D Executive VP-Administration Nov 10 '23 Buy 1.30 10,000 13,000 6,177,732 Nov 13 08:21 AM FROST PHILLIP MD ET AL CEO & Chairman Nov 09 '23 Buy 1.28 500,000 641,471 201,456,694 Nov 13 08:23 AM FROST PHILLIP MD ET AL CEO & Chairman Aug 17 '23 Buy 1.76 100,000 175,804 200,956,694 Aug 18 07:10 AM FROST PHILLIP MD ET AL CEO & Chairman Aug 14 '23 Buy 1.75 75,000 131,260 200,856,694 Aug 15 07:05 AM FROST PHILLIP MD ET AL CEO & Chairman Aug 09 '23 Buy 1.82 100,000 181,752 200,781,694 Aug 10 06:59 AM FROST PHILLIP MD ET AL CEO & Chairman Aug 07 '23 Buy 1.84 650,000 1,194,998 200,681,694 Aug 08 07:07 AM Nabel Gary J. Chief Innovation Officer May 05 '23 Buy 1.84 272,637 500,857 19,912,459 May 08 07:03 AM Nabel Gary J. Chief Innovation Officer May 05 '23 Buy 1.81 187,608 340,042 263,079 May 08 07:03 AM
Index -
P/E -
EPS (ttm) -0.07
Insider Own 40.67%
Shs Outstand 74.98M
Perf Week -6.78%
Market Cap 259.07M
Forward P/E 59.83
EPS next Y 0.06
Insider Trans 0.02%
Shs Float 44.68M
Perf Month -6.27%
Income -4.94M
PEG -
EPS next Q -0.02
Inst Own 15.47%
Short Float 3.32%
Perf Quarter 124.84%
Sales 83.57M
P/S 3.10
EPS this Y 78.57%
Inst Trans -19.26%
Short Ratio 4.62
Perf Half Y 168.75%
Book/sh 0.38
P/B 9.06
EPS next Y 483.33%
ROA -9.06%
Short Interest 1.48M
Perf Year 160.61%
Cash/sh 0.36
P/C 9.48
EPS next 5Y -
ROE -17.29%
52W Range 1.25 - 4.65
Perf YTD 140.56%
Dividend Est. -
P/FCF 37.60
EPS past 5Y 35.83%
ROI -15.91%
52W High -26.02%
Beta 1.98
Dividend TTM -
Quick Ratio 1.70
Sales past 5Y 22.27%
Gross Margin 60.76%
52W Low 175.20%
ATR (14) 0.35
Dividend Ex-Date -
Current Ratio 2.40
EPS Y/Y TTM 72.60%
Oper. Margin -3.95%
RSI (14) 50.28
Volatility 12.53% 11.04%
Employees 106
Debt/Eq 0.12
Sales Y/Y TTM 15.99%
Profit Margin -5.91%
Recom 1.00
Target Price 6.35
Option/Short Yes / Yes
LT Debt/Eq 0.09
EPS Q/Q 107.81%
Payout -
Rel Volume 0.56
Prev Close 3.39
Sales Surprise 1.84%
EPS Surprise 100.00%
Sales Q/Q 0.95%
Earnings Mar 06 AMC
Avg Volume 320.84K
Price 3.44
SMA20 -8.85%
SMA50 22.51%
SMA200 90.36%
Trades
Volume 180,257
Change 1.47%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-16-22 Downgrade
Oppenheimer
Outperform → Perform
Aug-11-22 Downgrade
B. Riley Securities
Buy → Neutral
$6 → $2.40
Mar-08-22 Initiated
ROTH Capital
Buy
$7
Oct-16-19 Initiated
Oppenheimer
Outperform
$6
Feb-14-19 Initiated
B. Riley FBR
Buy
$7
Nov-27-17 Resumed
H.C. Wainwright
Buy
$6 → $8
Sep-25-17 Initiated
Ladenburg Thalmann
Buy
$7
Jan-03-17 Initiated
Rodman & Renshaw
Buy
$6
Apr-25-24 08:34AM
Apr-24-24 08:34AM
Apr-23-24 08:32AM
Mar-26-24 08:32AM
Mar-07-24 01:59PM
10:37AM
Loading…
10:37AM
06:27AM
(Thomson Reuters StreetEvents)
Mar-06-24 09:53PM
04:04PM
Feb-21-24 08:32AM
Feb-05-24 08:32AM
Jan-26-24 04:08PM
Dec-20-23 09:04AM
Dec-12-23 10:30AM
Nov-30-23 08:34AM
08:32AM
Loading…
Nov-15-23 08:32AM
Nov-10-23 12:54PM
Nov-09-23 08:32AM
Nov-08-23 06:33PM
04:48PM
(Associated Press Finance)
04:02PM
Nov-01-23 08:34AM
Oct-31-23 08:34AM
Oct-26-23 08:32AM
Oct-02-23 08:32AM
Aug-24-23 08:32AM
Aug-12-23 09:04AM
Aug-10-23 10:38AM
(Thomson Reuters StreetEvents)
Aug-09-23 05:40PM
04:37PM
(Associated Press Finance)
04:02PM
Loading…
04:02PM
Aug-08-23 08:34AM
Aug-07-23 08:32AM
Aug-02-23 08:02AM
Jul-18-23 08:32AM
Jun-16-23 08:32AM
Jun-08-23 08:19AM
May-30-23 08:34AM
May-11-23 08:34AM
May-10-23 05:35PM
04:32PM
04:02PM
May-02-23 08:32AM
06:31AM
Apr-12-23 01:04PM
Mar-27-23 06:43AM
Mar-10-23 05:23AM
02:28AM
Mar-09-23 09:06AM
(Thomson Reuters StreetEvents) -10.38%
Mar-08-23 06:25PM
04:02PM
Mar-06-23 08:34AM
Mar-02-23 10:00AM
Mar-01-23 10:00AM
Feb-27-23 08:32AM
Feb-22-23 08:34AM
Feb-21-23 08:32AM
Jan-31-23 08:32AM
Jan-17-23 08:28AM
Jan-15-23 08:52AM
Jan-12-23 08:34AM
Jan-05-23 08:33AM
Dec-27-22 08:30AM
Dec-19-22 09:35AM
Dec-16-22 09:35AM
Nov-11-22 08:12AM
Nov-09-22 05:02AM
Nov-02-22 05:35PM
04:02PM
11:40AM
Oct-26-22 08:35AM
Oct-24-22 08:32AM
Oct-11-22 07:32AM
Oct-06-22 08:53AM
Oct-04-22 06:32AM
Oct-03-22 07:30AM
Sep-19-22 06:05PM
Sep-01-22 06:32AM
Aug-29-22 03:07PM
Aug-24-22 09:00AM
(American City Business Journals)
09:00AM
Aug-15-22 06:34AM
Aug-10-22 05:45PM
04:02PM
Aug-08-22 09:41AM
Aug-02-22 06:32AM
Jul-10-22 09:57AM
Jul-07-22 06:32AM
Jun-22-22 06:07AM
Jun-15-22 06:34AM
Jun-10-22 06:32AM
Jun-07-22 01:33PM
Jun-02-22 06:34AM
Jun-01-22 06:32AM
May-22-22 08:17AM
May-20-22 10:02AM
May-19-22 04:34PM
May-17-22 08:27AM
(Simply Wall St.) +15.09%
06:34AM
May-12-22 05:35PM
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Gerber Brianna Chief Financial Officer Dec 01 '23 Buy 1.41 5,000 7,050 27,436 Dec 04 04:12 PM Jaksch Frank L Jr Director Jun 12 '23 Buy 1.69 7,000 11,830 231,339 Jun 13 04:50 PM Fried Robert N Chief Executive Officer May 31 '23 Buy 1.42 7,000 9,940 95,001 Jun 01 04:27 PM Rubin Steven D Director May 25 '23 Buy 1.46 7,000 10,220 7,000 May 30 04:13 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite